Matricelf Ltd Stock

MTLF

IL0011767915

Biotechnology & Medical Research

Delayed TEL AVIV STOCK EXCHANGE 09:41:21 2026-10-05 am EDT			5-day change	1st Jan Change
249.50 ^ILa	-2.16%		-2.58%	-54.71%

Sep. 03	Matricelf Receives FDA Feedback Supporting Key Elements Of Proposed First In Human Clinical Trial For NewRal Spinal Cord Injury Program	CI
Aug. 27	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Matricelf Ltd is an Israel-based company engaged in the biotechnology sector. The Company operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The Company focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinsonâ€™s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-05	ILA 249.50	-2.16%	93,543
26-10-01	ILA 255.00	-1.09%	108,748
26-09-30	ILA 257.80	+0.94%	36,537
26-09-29	ILA 255.40	-0.27%	12,737

Delayed Quote TEL AVIV STOCK EXCHANGE

More quotes

Stock Market
Stocks
MTLF Stock

Stock markets for all

100% Free Registration

Market Cap	77.3M 0 25.28M 22.46M 20.96M 19.11M 36.04M 2.43B 36.37M 254M 98.31M 1.24B 94.92M 92.86M 3.99B	P/E 2024	-3.74x	P/E 2025	-3.65x
Enterprise Value	57.16M 0 18.69M 16.61M 15.5M 14.13M 26.65M 1.8B 26.9M 188M 72.7M 919M 70.19M 68.66M 2.95B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	77.85%	Yield 2024 *	-	Yield 2025	-

Sep. 03	Matricelf Receives FDA Feedback Supporting Key Elements Of Proposed First In Human Clinical Trial For NewRal Spinal Cord Injury Program	CI
Aug. 27	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI
Jul. 09	Matricelf Ltd. Receives Approval to Begin Patient Identification and Blood Collection for Planned First-In-Human Spinal Cord Injury Study	CI
Jun. 22	Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord Injury	CI
Jun. 17	Matricelf Completes GLP Safety Study for Engineered Neural Tissue Implant	CI
Mar. 30	Matricelf Ltd. Enters into Collaborative Research Agreement with CiRA Foundation	CI
Mar. 24	Matricelf Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 24	Matricelf and Sheba Medical Center Enter Strategic Collaboration to Advance First in Human Clinical Program in Spinal Cord Injury	CI
Mar. 23	Matricelf Ltd Auditor Raises 'Going Concern' Doubt	CI
Mar. 04	Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord Implant	CI
Mar. 03	Matricelf Ltd. Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	CI
Mar. 03	Matricelf Ltd. (Tase Mtlf) signs MoU to establish subsidiary for commercialization of Parkinson's disease therapy	RE
Feb. 27	Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of Directors	CI

Sep. 03	Matricelf Receives FDA Feedback Supporting Key Elements of Proposed First in Human Clinical Trial for NewRal Spinal Cord Injury Program	PR
Jul. 09	Matricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing Milestones	PR
Jun. 23	Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury	AQ
Mar. 03	Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	PR
Mar. 02	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	AQ

1 week	-0.43%
Current month	-1.09%
1 month	-9.41%
3 months	-4.46%
6 months	-23.24%
Current year	-53.71%

1 week	240	260
1 month	240	314.8
Current year	212	853
1 year	212	853
3 years	204	853
5 years	204	1,555
10 years	204	1,555

Matricelf Ltd Stock

Stocks

MTLF

IL0011767915

Biotechnology & Medical Research

Valuation: Matricelf Ltd

Chart: Matricelf Ltd

Latest news: Matricelf Ltd

Press Releases: Matricelf Ltd

Quotes and Performance

Price Extremes

Managers and Directors: Matricelf Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Asaf Toker CEO	Chief Executive Officer	54	2019-05-31
Tal Dvir CTO	Chief Tech/Sci/R&D Officer	51	2019-05-31
Alon Sinai COO	Chief Operating Officer	59	2019-06-30

Director	Title	Age	Since
Alon Sinai BRD	Director/Board Member	59	2019-06-30
Tal Dvir BRD	Director/Board Member	51	2019-05-31
Stanley Hirsch BRD	Director/Board Member	69	2022-07-26

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MATRICELF LTD	0.00%	-0.43%	-43.50%	-40.30%	25.28M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	+1.13%	-2.34%	+21.33%	+80.84%	57.39B
LONZA GROUP AG	+1.57%	-1.37%	+3.41%	+37.22%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+342.39%	+748.97%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+24.96%	+31.45%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+4.13%	+111.69%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+54.06%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	+1.56%	+3.75%	+31.90%	+29.14%	28.53B
BIONTECH SE	+0.05%	-1.64%	-8.14%	-12.10%	24.34B
Average	+0.74%	-0.71%	+43.52%	+113.52%	39.06B
Weighted average by Cap.	+1.16%	-0.84%	+57.46%	+139.96%

	2024	2025
Net sales	-	-
Net income	-15.58M -0 -5.1M -4.53M -4.23M -3.85M -7.26M -490M -7.33M -51.14M -19.82M -250M -19.13M -18.72M -804M	-27.82M -0 -9.1M -8.08M -7.55M -6.88M -12.97M -875M -13.09M -91.31M -35.38M -447M -34.16M -33.42M -1.44B
Net Debt	-10.68M -0 -3.49M -3.1M -2.9M -2.64M -4.98M -336M -5.03M -35.05M -13.58M -172M -13.11M -12.83M -551M	-20.14M -0 -6.59M -5.85M -5.46M -4.98M -9.39M -633M -9.48M -66.1M -25.61M -324M -24.73M -24.19M -1.04B